FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280643595> ?p ?o ?g. }

• W4280643595 abstract "Antipsychotic drugs are primarily efficacious in treating positive symptoms by blocking the dopamine D2 receptor, but they fail to substantially improve negative symptoms and cognitive deficits. The limited efficacy may be attributed to the fact that the pathophysiology of psychosis involves multiple neurotransmitter systems. In patients with chronic schizophrenia, memantine, a non-competitive glutamatergic NMDA receptor antagonist, shows promise for ameliorating negative symptoms and improving cognition. Yet, it is unknown how memantine modulates glutamate levels, and memantine has not been investigated in patients with first-episode psychosis.This investigator-initiated double-blinded randomized controlled trial is designed to (1) test the clinical effects on negative symptoms of add-on memantine to antipsychotic medication, and (2) neurobiologically characterize the responders to add-on memantine.Antipsychotic-naïve patients with first-episode psychosis will be randomized to 12 weeks treatment with [amisulpride + memantine] or [amisulpride + placebo]. We aim for a minimum of 18 patients in each treatment arm to complete the trial. Brain mapping will be performed before and after 12 weeks focusing on glutamate and neuromelanin in predefined regions. Regional glutamate levels will be probed with proton magnetic resonance spectroscopy (MRS), while neuromelanin signal will be mapped with neuromelanin-sensitive magnetic resonance imaging (MRI). We will also perform structural and diffusion weighted, whole-brain MRI. MRS and MRI will be performed at an ultra-high field strength (7 Tesla). Alongside, participants undergo clinical and neuropsychological assessments. Twenty matched healthy controls will undergo similar baseline- and 12-week examinations, but without receiving treatment.The primary endpoint is negative symptom severity. Secondary outcomes comprise: (i) clinical endpoints related to cognition, psychotic symptoms, side effects, and (ii) neurobiological endpoints related to regional glutamate- and neuromelanin levels, and structural brain changes.We hypothesize that add-on memantine to amisulpride will be superior to amisulpride monotherapy in reducing negative symptoms, and that this effect will correlate with thalamic glutamate levels. Moreover, we anticipate that add-on memantine will restore regional white matter integrity and improve cognitive functioning.By combining two licensed, off-patent drugs, AMEND aims to optimize treatment of psychosis while investigating the memantine response. Alongside, AMEND will provide neurobiological insights to effects of dual receptor modulation, which may enable future stratification of patients with first-episode psychosis before initial antipsychotic treatment.[ClinicalTrials.gov], identifier [NCT04789915]." @default.
• W4280643595 created "2022-05-22" @default.
• W4280643595 creator A5000829712 @default.
• W4280643595 creator A5009776017 @default.
• W4280643595 creator A5011264157 @default.
• W4280643595 creator A5015378340 @default.
• W4280643595 creator A5019994365 @default.
• W4280643595 creator A5025185677 @default.
• W4280643595 creator A5034093325 @default.
• W4280643595 creator A5035796984 @default.
• W4280643595 creator A5048696924 @default.
• W4280643595 creator A5055136911 @default.
• W4280643595 creator A5057614507 @default.
• W4280643595 creator A5062126653 @default.
• W4280643595 creator A5067524733 @default.
• W4280643595 creator A5067647525 @default.
• W4280643595 creator A5074014109 @default.
• W4280643595 creator A5086021311 @default.
• W4280643595 creator A5087485044 @default.
• W4280643595 creator A5088557617 @default.
• W4280643595 date "2022-05-20" @default.
• W4280643595 modified "2023-10-01" @default.
• W4280643595 title "Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol" @default.
• W4280643595 cites W1532044842 @default.
• W4280643595 cites W1688754235 @default.
• W4280643595 cites W1843252001 @default.
• W4280643595 cites W1876943069 @default.
• W4280643595 cites W1993727269 @default.
• W4280643595 cites W2002367629 @default.
• W4280643595 cites W2009020263 @default.
• W4280643595 cites W2009570830 @default.
• W4280643595 cites W2018927895 @default.
• W4280643595 cites W2022429200 @default.
• W4280643595 cites W2025058645 @default.
• W4280643595 cites W2036614057 @default.
• W4280643595 cites W2047120106 @default.
• W4280643595 cites W2047587201 @default.
• W4280643595 cites W2075675414 @default.
• W4280643595 cites W2076669993 @default.
• W4280643595 cites W2080105564 @default.
• W4280643595 cites W2087183527 @default.
• W4280643595 cites W2093696735 @default.
• W4280643595 cites W2096192353 @default.
• W4280643595 cites W2098644261 @default.
• W4280643595 cites W2119226169 @default.
• W4280643595 cites W2136022845 @default.
• W4280643595 cites W2140606211 @default.
• W4280643595 cites W2144706830 @default.
• W4280643595 cites W2149634179 @default.
• W4280643595 cites W2149639459 @default.
• W4280643595 cites W2151330137 @default.
• W4280643595 cites W2161401886 @default.
• W4280643595 cites W2162950935 @default.
• W4280643595 cites W2170946434 @default.
• W4280643595 cites W2172035249 @default.
• W4280643595 cites W2172249063 @default.
• W4280643595 cites W2415625988 @default.
• W4280643595 cites W2560754155 @default.
• W4280643595 cites W2582474237 @default.
• W4280643595 cites W2605982210 @default.
• W4280643595 cites W2615810296 @default.
• W4280643595 cites W2768623814 @default.
• W4280643595 cites W2775173797 @default.
• W4280643595 cites W2788615095 @default.
• W4280643595 cites W2789041680 @default.
• W4280643595 cites W2795849858 @default.
• W4280643595 cites W2799778639 @default.
• W4280643595 cites W2807268163 @default.
• W4280643595 cites W2906768105 @default.
• W4280643595 cites W2909170118 @default.
• W4280643595 cites W2911176868 @default.
• W4280643595 cites W2913142180 @default.
• W4280643595 cites W2913588197 @default.
• W4280643595 cites W2915476106 @default.
• W4280643595 cites W2917910816 @default.
• W4280643595 cites W2947644989 @default.
• W4280643595 cites W2960385316 @default.
• W4280643595 cites W2966095247 @default.
• W4280643595 cites W2968731159 @default.
• W4280643595 cites W2968974743 @default.
• W4280643595 cites W2973351498 @default.
• W4280643595 cites W2990116051 @default.
• W4280643595 cites W2994997975 @default.
• W4280643595 cites W3002770094 @default.
• W4280643595 cites W3003610748 @default.
• W4280643595 cites W3006093789 @default.
• W4280643595 cites W3008160924 @default.
• W4280643595 cites W3011624175 @default.
• W4280643595 cites W3012808443 @default.
• W4280643595 cites W3015543532 @default.
• W4280643595 cites W3040903862 @default.
• W4280643595 cites W3044660945 @default.
• W4280643595 cites W3048593133 @default.
• W4280643595 cites W3091721457 @default.
• W4280643595 cites W3094276117 @default.
• W4280643595 cites W3161529151 @default.
• W4280643595 cites W3183060387 @default.
• W4280643595 cites W4210381002 @default.
• W4280643595 doi "https://doi.org/10.3389/fpsyt.2022.889572" @default.
• W4280643595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35669271" @default.

• next